BiomX (PHGE) to Release Earnings on Tuesday

BiomX (NYSEAMERICAN:PHGE) will likely be posting its results before the market opens on Tuesday, March 24th. Analysts expect BiomX to post earnings of ($4.61) per share for the quarter.

BiomX (NYSEAMERICAN:PHGE) last posted its earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. On average, analysts expect BiomX to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

BiomX Stock Down 1.8%

PHGE stock opened at $4.89 on Friday. The firm has a market capitalization of $7.78 million, a P/E ratio of -0.19 and a beta of 1.68. BiomX has a 52 week low of $1.50 and a 52 week high of $14.71. The company has a fifty day simple moving average of $5.03 and a two-hundred day simple moving average of $6.28.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a report on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, BiomX presently has an average rating of “Hold” and an average target price of $26.00.

Insider Activity

In other news, Director Reuven Yeganeh sold 530,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 21.80% of the company’s stock.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by institutional investors.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.